XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.2
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
May 30, 2024
Feb. 05, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Asset Acquisition [Line Items]            
Research and development     $ 1,138,380 $ 400,750 $ 1,567,640 $ 807,391
Escient            
Asset Acquisition [Line Items]            
Payments for asset acquisitions $ 782,500          
Asset acquisition, consideration transferred, transaction cost 2,500          
Asset acquisition, consideration transferred 785,000          
Asset acquisition, compensation expense     31,500      
In-process research and development assets 679,388          
Research and development     $ 679,400   $ 679,400  
Escient | In Process Research and Development - EP262            
Asset Acquisition [Line Items]            
In-process research and development assets 644,800          
Escient | In Process Research and Development - EP547            
Asset Acquisition [Line Items]            
In-process research and development assets $ 34,600          
Maximum | Xencor            
Asset Acquisition [Line Items]            
Uncured material breach, written notice period   120 days        
Payment obligation breach, written notice period   30 days        
Minimum | Xencor            
Asset Acquisition [Line Items]            
Advance written notice period   90 days        
Development and Regulatory Milestones | Maximum | Xencor            
Asset Acquisition [Line Items]            
Additional milestone payments under the license agreement   $ 186,500        
Commercialization Milestones | Maximum | Xencor            
Asset Acquisition [Line Items]            
Additional milestone payments under the license agreement   $ 50,000        
Expiration period   11 years        
MorphoSys AG            
Asset Acquisition [Line Items]            
Payment to acquire license agreement   $ 25,000